This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail’s Galleri test aims to detect 50 types of cancer from a simple blood sample, but its potential to be covered by Medicare and other insurers depends on FDA approval. Despite its promise, a major study couldn't conclusively show it could identify cancers in later stages, raising questions about its effectiveness. This situation underscores the need for rigorous evidence before widespread adoption in healthcare, especially for tests that could significantly impact coverage and patient outcomes.